Outcomes of Hydroxychloroquine Treatment Among Hospitalized COVID-19 Patients in the United States- Real-World Evidence From a Federated Electronic Medical Record Network
Singh, S.; Khan, A.; Chowdhry, M.; Chatterjee, A.
Show abstract
On March 28, 2020, in response to the rapidly accelerating COVID-19 pandemic, U.S FDA issued emergency use authorization for hydroxychloroquine (HCQ) in hospitalized COVID-19 patients based on limited in-vitro and anecdotal clinical data. Analysis of the accumulated real-world data utilizing electronic medical records (EMR) could indicate HCQ therapy benefits as we await the results of clinical trials. However, any such analysis of retrospective observational data should account for variables such as demographics and comorbidities that could affect treatment strategies or outcomes. Therefore, we report the outcomes of HCQ treatment in a propensity-matched cohort of COVID-19 hospitalized patients. Our analysis of a large retrospective cohort of hospitalized COVID-19 patients treated with HCQ did not show benefits in mortality or the need for mechanical ventilation when compared to a matched cohort of patients who did not receive HCQ.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Hydroxychloroquine For The Treatment Of Severe Respiratory Infection By COVID-19: A Randomized Controlled Trial 94%
- Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study 94%
- A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19) 93%
Similar papers in this journal
- A Multi-center, Prospective, Observational-cohort controlled study of Clinical Outcomes following COVID-19 Convalescent plasma therapy in hospitalized COVID-19 patients 92%
- Early Short Course Corticosteroids in Hospitalized Patients with COVID-19 91%
- Compassionate Use of REGEN-COV ® in Patients with COVID-19 and Immunodeficiency-Associated Antibody Disorders 91%
Similar papers in this journal
- Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19 94%
- Opaganib in COVID-19 pneumonia: Results of a randomized, placebo-controlled Phase 2a trial 92%
- Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients with Moderate to Severe COVID 19: A Phase IIa Trial 91%
Similar papers in this journal
- A placebo-controlled double blind trial of hydroxychloroquine in mild-to-moderate COVID-19 94%
- Hydroxychloroquine and mortality risk of patients with COVID-19: a systematic review and meta-analysis of human comparative studies 94%
- An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results from the DisCoVeRy trial 92%
Similar papers in this journal
- Early initiation of corticosteroids in patients hospitalized with COVID-19 not requiring intensive respiratory support: cohort study 92%
- A Randomized Trial of Otilimab in Severe COVID-19 Pneumonia (OSCAR) 91%
- Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.